nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—CYP1A1—head and neck cancer	0.55	1	CbGaD
Rabeprazole—ABCG2—Fluorouracil—head and neck cancer	0.0748	0.243	CbGbCtD
Rabeprazole—CYP2D6—Hydroxyurea—head and neck cancer	0.0665	0.216	CbGbCtD
Rabeprazole—ABCG2—Docetaxel—head and neck cancer	0.0571	0.186	CbGbCtD
Rabeprazole—CYP1A2—Fluorouracil—head and neck cancer	0.0308	0.1	CbGbCtD
Rabeprazole—CYP2C9—Fluorouracil—head and neck cancer	0.0278	0.0903	CbGbCtD
Rabeprazole—CYP2D6—Vinblastine—head and neck cancer	0.0235	0.0765	CbGbCtD
Rabeprazole—CYP3A4—Vinblastine—head and neck cancer	0.015	0.0486	CbGbCtD
Rabeprazole—CYP3A4—Docetaxel—head and neck cancer	0.0123	0.0401	CbGbCtD
Rabeprazole—ATP4B—Ion transport by P-type ATPases—ATP7B—head and neck cancer	0.0038	0.107	CbGpPWpGaD
Rabeprazole—ATP4A—Ion transport by P-type ATPases—ATP7B—head and neck cancer	0.00339	0.0953	CbGpPWpGaD
Rabeprazole—ATP4A—larynx—head and neck cancer	0.00161	0.43	CbGeAlD
Rabeprazole—Omeprazole—CYP1A1—head and neck cancer	0.00143	0.522	CrCbGaD
Rabeprazole—ATP4B—Ion channel transport—ATP7B—head and neck cancer	0.00132	0.037	CbGpPWpGaD
Rabeprazole—CYP1A2—Arylamine metabolism—NAT2—head and neck cancer	0.0013	0.0367	CbGpPWpGaD
Rabeprazole—Lansoprazole—CYP1A1—head and neck cancer	0.0013	0.478	CrCbGaD
Rabeprazole—ATP4A—Ion channel transport—ATP7B—head and neck cancer	0.00117	0.033	CbGpPWpGaD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—XRCC3—head and neck cancer	0.00102	0.0287	CbGpPWpGaD
Rabeprazole—Blepharitis—Fluorouracil—head and neck cancer	0.00101	0.0101	CcSEcCtD
Rabeprazole—Lacrimal disorder—Docetaxel—head and neck cancer	0.00101	0.0101	CcSEcCtD
Rabeprazole—Bone pain—Vinblastine—head and neck cancer	0.000992	0.00991	CcSEcCtD
Rabeprazole—Ascites—Docetaxel—head and neck cancer	0.000991	0.0099	CcSEcCtD
Rabeprazole—Nail disorder—Fluorouracil—head and neck cancer	0.000962	0.00961	CcSEcCtD
Rabeprazole—Interstitial pneumonia—Docetaxel—head and neck cancer	0.000932	0.00931	CcSEcCtD
Rabeprazole—Neoplasm—Vinblastine—head and neck cancer	0.00086	0.00858	CcSEcCtD
Rabeprazole—Neoplasm—Hydroxyurea—head and neck cancer	0.000784	0.00783	CcSEcCtD
Rabeprazole—Deafness—Vinblastine—head and neck cancer	0.000771	0.00771	CcSEcCtD
Rabeprazole—Eruption—Docetaxel—head and neck cancer	0.000732	0.00731	CcSEcCtD
Rabeprazole—Disorientation—Hydroxyurea—head and neck cancer	0.000704	0.00703	CcSEcCtD
Rabeprazole—Embolism—Docetaxel—head and neck cancer	0.000702	0.00701	CcSEcCtD
Rabeprazole—Nail disorder—Docetaxel—head and neck cancer	0.000694	0.00694	CcSEcCtD
Rabeprazole—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.000687	0.00687	CcSEcCtD
Rabeprazole—Cellulitis—Fluorouracil—head and neck cancer	0.000686	0.00685	CcSEcCtD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—DPYD—head and neck cancer	0.000678	0.0191	CbGpPWpGaD
Rabeprazole—Herpes simplex—Fluorouracil—head and neck cancer	0.000677	0.00676	CcSEcCtD
Rabeprazole—Leukocytosis—Fluorouracil—head and neck cancer	0.000664	0.00663	CcSEcCtD
Rabeprazole—Neuralgia—Docetaxel—head and neck cancer	0.000648	0.00648	CcSEcCtD
Rabeprazole—Interstitial lung disease—Docetaxel—head and neck cancer	0.000636	0.00636	CcSEcCtD
Rabeprazole—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000623	0.0175	CbGpPWpGaD
Rabeprazole—Dermatitis contact—Fluorouracil—head and neck cancer	0.000617	0.00616	CcSEcCtD
Rabeprazole—Face oedema—Hydroxyurea—head and neck cancer	0.000608	0.00607	CcSEcCtD
Rabeprazole—Angina pectoris—Vinblastine—head and neck cancer	0.000581	0.0058	CcSEcCtD
Rabeprazole—Otitis media—Docetaxel—head and neck cancer	0.000579	0.00578	CcSEcCtD
Rabeprazole—Oesophagitis—Fluorouracil—head and neck cancer	0.00057	0.0057	CcSEcCtD
Rabeprazole—Coma—Fluorouracil—head and neck cancer	0.00057	0.0057	CcSEcCtD
Rabeprazole—CYP1A2—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00057	0.016	CbGpPWpGaD
Rabeprazole—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000568	0.016	CbGpPWpGaD
Rabeprazole—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000567	0.0159	CbGpPWpGaD
Rabeprazole—Pancytopenia—Vinblastine—head and neck cancer	0.000566	0.00566	CcSEcCtD
Rabeprazole—Pancreatitis—Hydroxyurea—head and neck cancer	0.000533	0.00533	CcSEcCtD
Rabeprazole—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000524	0.00524	CcSEcCtD
Rabeprazole—Thrombophlebitis—Fluorouracil—head and neck cancer	0.000523	0.00523	CcSEcCtD
Rabeprazole—Myocardial infarction—Vinblastine—head and neck cancer	0.000521	0.00521	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000521	0.00521	CcSEcCtD
Rabeprazole—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000517	0.0145	CbGpPWpGaD
Rabeprazole—Pancytopenia—Hydroxyurea—head and neck cancer	0.000517	0.00516	CcSEcCtD
Rabeprazole—Photosensitivity—Fluorouracil—head and neck cancer	0.000516	0.00515	CcSEcCtD
Rabeprazole—Dysuria—Hydroxyurea—head and neck cancer	0.000509	0.00508	CcSEcCtD
Rabeprazole—Neutropenia—Hydroxyurea—head and neck cancer	0.000509	0.00508	CcSEcCtD
Rabeprazole—Disorientation—Fluorouracil—head and neck cancer	0.000506	0.00506	CcSEcCtD
Rabeprazole—Agranulocytosis—Vinblastine—head and neck cancer	0.000496	0.00496	CcSEcCtD
Rabeprazole—Weight increased—Hydroxyurea—head and neck cancer	0.000495	0.00494	CcSEcCtD
Rabeprazole—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—head and neck cancer	0.000485	0.0136	CbGpPWpGaD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—SMUG1—head and neck cancer	0.000482	0.0136	CbGpPWpGaD
Rabeprazole—Amnesia—Fluorouracil—head and neck cancer	0.000482	0.00482	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000475	0.00475	CcSEcCtD
Rabeprazole—Pharyngitis—Vinblastine—head and neck cancer	0.000474	0.00473	CcSEcCtD
Rabeprazole—Stomatitis—Hydroxyurea—head and neck cancer	0.000473	0.00472	CcSEcCtD
Rabeprazole—Bone pain—Docetaxel—head and neck cancer	0.00047	0.0047	CcSEcCtD
Rabeprazole—Respiratory failure—Docetaxel—head and neck cancer	0.000459	0.00458	CcSEcCtD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000458	0.0129	CbGpPWpGaD
Rabeprazole—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000453	0.00452	CcSEcCtD
Rabeprazole—Osteoarthritis—Fluorouracil—head and neck cancer	0.000453	0.00452	CcSEcCtD
Rabeprazole—Pulmonary embolism—Docetaxel—head and neck cancer	0.00045	0.0045	CcSEcCtD
Rabeprazole—Injection site reaction—Docetaxel—head and neck cancer	0.000448	0.00447	CcSEcCtD
Rabeprazole—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—head and neck cancer	0.000442	0.0124	CbGpPWpGaD
Rabeprazole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—head and neck cancer	0.00044	0.0124	CbGpPWpGaD
Rabeprazole—Colitis—Docetaxel—head and neck cancer	0.000432	0.00432	CcSEcCtD
Rabeprazole—Candida infection—Docetaxel—head and neck cancer	0.00043	0.0043	CcSEcCtD
Rabeprazole—ATP4A—neck—head and neck cancer	0.000427	0.114	CbGeAlD
Rabeprazole—Neuropathy—Docetaxel—head and neck cancer	0.000423	0.00422	CcSEcCtD
Rabeprazole—Alopecia—Vinblastine—head and neck cancer	0.000422	0.00421	CcSEcCtD
Rabeprazole—CYP1A1—Estrogen metabolism—GSTM1—head and neck cancer	0.00042	0.0118	CbGpPWpGaD
Rabeprazole—Dry skin—Fluorouracil—head and neck cancer	0.000415	0.00415	CcSEcCtD
Rabeprazole—Oesophagitis—Docetaxel—head and neck cancer	0.000412	0.00411	CcSEcCtD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000408	0.0115	CbGpPWpGaD
Rabeprazole—Neoplasm—Docetaxel—head and neck cancer	0.000407	0.00407	CcSEcCtD
Rabeprazole—Angiopathy—Hydroxyurea—head and neck cancer	0.000395	0.00395	CcSEcCtD
Rabeprazole—Dysphagia—Fluorouracil—head and neck cancer	0.000392	0.00391	CcSEcCtD
Rabeprazole—Chills—Hydroxyurea—head and neck cancer	0.000391	0.0039	CcSEcCtD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TYMS—head and neck cancer	0.000386	0.0109	CbGpPWpGaD
Rabeprazole—Ill-defined disorder—Vinblastine—head and neck cancer	0.000386	0.00385	CcSEcCtD
Rabeprazole—Alopecia—Hydroxyurea—head and neck cancer	0.000385	0.00384	CcSEcCtD
Rabeprazole—Anaemia—Vinblastine—head and neck cancer	0.000384	0.00384	CcSEcCtD
Rabeprazole—Angina pectoris—Fluorouracil—head and neck cancer	0.000381	0.00381	CcSEcCtD
Rabeprazole—Erythema—Hydroxyurea—head and neck cancer	0.000379	0.00379	CcSEcCtD
Rabeprazole—Thrombophlebitis—Docetaxel—head and neck cancer	0.000378	0.00377	CcSEcCtD
Rabeprazole—Malaise—Vinblastine—head and neck cancer	0.000375	0.00374	CcSEcCtD
Rabeprazole—Vertigo—Vinblastine—head and neck cancer	0.000373	0.00373	CcSEcCtD
Rabeprazole—Leukopenia—Vinblastine—head and neck cancer	0.000372	0.00372	CcSEcCtD
Rabeprazole—Pancytopenia—Fluorouracil—head and neck cancer	0.000372	0.00371	CcSEcCtD
Rabeprazole—Deafness—Docetaxel—head and neck cancer	0.000365	0.00365	CcSEcCtD
Rabeprazole—Convulsion—Vinblastine—head and neck cancer	0.00036	0.0036	CcSEcCtD
Rabeprazole—Hypertension—Vinblastine—head and neck cancer	0.000359	0.00358	CcSEcCtD
Rabeprazole—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000357	0.00357	CcSEcCtD
Rabeprazole—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000352	0.00351	CcSEcCtD
Rabeprazole—Pneumonia—Fluorouracil—head and neck cancer	0.000351	0.00351	CcSEcCtD
Rabeprazole—Anaemia—Hydroxyurea—head and neck cancer	0.00035	0.0035	CcSEcCtD
Rabeprazole—Discomfort—Vinblastine—head and neck cancer	0.00035	0.00349	CcSEcCtD
Rabeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000349	0.0098	CbGpPWpGaD
Rabeprazole—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000344	0.00344	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000342	0.00342	CcSEcCtD
Rabeprazole—Myocardial infarction—Fluorouracil—head and neck cancer	0.000342	0.00342	CcSEcCtD
Rabeprazole—Malaise—Hydroxyurea—head and neck cancer	0.000342	0.00341	CcSEcCtD
Rabeprazole—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—head and neck cancer	0.000341	0.00959	CbGpPWpGaD
Rabeprazole—Stomatitis—Fluorouracil—head and neck cancer	0.00034	0.0034	CcSEcCtD
Rabeprazole—Conjunctivitis—Fluorouracil—head and neck cancer	0.000339	0.00339	CcSEcCtD
Rabeprazole—Urinary tract infection—Fluorouracil—head and neck cancer	0.000339	0.00339	CcSEcCtD
Rabeprazole—Leukopenia—Hydroxyurea—head and neck cancer	0.000339	0.00339	CcSEcCtD
Rabeprazole—Thrombocytopenia—Vinblastine—head and neck cancer	0.000332	0.00332	CcSEcCtD
Rabeprazole—Epistaxis—Fluorouracil—head and neck cancer	0.000329	0.00329	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—CYP1A1—head and neck cancer	0.000329	0.00926	CbGpPWpGaD
Rabeprazole—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000329	0.00925	CbGpPWpGaD
Rabeprazole—Convulsion—Hydroxyurea—head and neck cancer	0.000328	0.00328	CcSEcCtD
Rabeprazole—Hyponatraemia—Docetaxel—head and neck cancer	0.000328	0.00328	CcSEcCtD
Rabeprazole—Sinusitis—Fluorouracil—head and neck cancer	0.000328	0.00327	CcSEcCtD
Rabeprazole—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000327	0.00327	CcSEcCtD
Rabeprazole—Agranulocytosis—Fluorouracil—head and neck cancer	0.000326	0.00325	CcSEcCtD
Rabeprazole—Anorexia—Vinblastine—head and neck cancer	0.000323	0.00323	CcSEcCtD
Rabeprazole—Migraine—Docetaxel—head and neck cancer	0.000322	0.00321	CcSEcCtD
Rabeprazole—Discomfort—Hydroxyurea—head and neck cancer	0.000319	0.00318	CcSEcCtD
Rabeprazole—Rhinitis—Fluorouracil—head and neck cancer	0.000314	0.00314	CcSEcCtD
Rabeprazole—Pharyngitis—Fluorouracil—head and neck cancer	0.000311	0.00311	CcSEcCtD
Rabeprazole—Oedema—Hydroxyurea—head and neck cancer	0.000309	0.00309	CcSEcCtD
Rabeprazole—ATP4A—connective tissue—head and neck cancer	0.000306	0.0817	CbGeAlD
Rabeprazole—Paraesthesia—Vinblastine—head and neck cancer	0.000305	0.00304	CcSEcCtD
Rabeprazole—Dehydration—Docetaxel—head and neck cancer	0.000304	0.00304	CcSEcCtD
Rabeprazole—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000303	0.00302	CcSEcCtD
Rabeprazole—Liver function test abnormal—Docetaxel—head and neck cancer	0.000302	0.00301	CcSEcCtD
Rabeprazole—Dry skin—Docetaxel—head and neck cancer	0.0003	0.00299	CcSEcCtD
Rabeprazole—CYP2C19—Xenobiotics—CYP1A1—head and neck cancer	0.000299	0.00842	CbGpPWpGaD
Rabeprazole—Abdominal pain upper—Docetaxel—head and neck cancer	0.000299	0.00298	CcSEcCtD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.000298	0.00838	CbGpPWpGaD
Rabeprazole—Anorexia—Hydroxyurea—head and neck cancer	0.000295	0.00294	CcSEcCtD
Rabeprazole—Decreased appetite—Vinblastine—head and neck cancer	0.000295	0.00294	CcSEcCtD
Rabeprazole—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000294	0.00294	CcSEcCtD
Rabeprazole—ATP4A—epithelium—head and neck cancer	0.000291	0.0776	CbGeAlD
Rabeprazole—Constipation—Vinblastine—head and neck cancer	0.00029	0.0029	CcSEcCtD
Rabeprazole—Pain—Vinblastine—head and neck cancer	0.00029	0.0029	CcSEcCtD
Rabeprazole—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000288	0.00288	CcSEcCtD
Rabeprazole—CYP2C19—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000288	0.00809	CbGpPWpGaD
Rabeprazole—Dysphagia—Docetaxel—head and neck cancer	0.000283	0.00282	CcSEcCtD
Rabeprazole—Arrhythmia—Fluorouracil—head and neck cancer	0.00028	0.0028	CcSEcCtD
Rabeprazole—CYP1A1—Oxidative Stress—SOD2—head and neck cancer	0.00028	0.00787	CbGpPWpGaD
Rabeprazole—Feeling abnormal—Vinblastine—head and neck cancer	0.000279	0.00279	CcSEcCtD
Rabeprazole—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000279	0.00784	CbGpPWpGaD
Rabeprazole—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000277	0.00277	CcSEcCtD
Rabeprazole—Alopecia—Fluorouracil—head and neck cancer	0.000277	0.00277	CcSEcCtD
Rabeprazole—Dyspnoea—Hydroxyurea—head and neck cancer	0.000276	0.00275	CcSEcCtD
Rabeprazole—Angina pectoris—Docetaxel—head and neck cancer	0.000275	0.00275	CcSEcCtD
Rabeprazole—CYP2D6—Xenobiotics—CYP1A1—head and neck cancer	0.000275	0.00774	CbGpPWpGaD
Rabeprazole—Somnolence—Hydroxyurea—head and neck cancer	0.000275	0.00275	CcSEcCtD
Rabeprazole—CYP2C9—Xenobiotics—CYP1A1—head and neck cancer	0.000273	0.00767	CbGpPWpGaD
Rabeprazole—Erythema—Fluorouracil—head and neck cancer	0.000273	0.00272	CcSEcCtD
Rabeprazole—Dyspepsia—Hydroxyurea—head and neck cancer	0.000272	0.00272	CcSEcCtD
Rabeprazole—Decreased appetite—Hydroxyurea—head and neck cancer	0.000269	0.00269	CcSEcCtD
Rabeprazole—Pancytopenia—Docetaxel—head and neck cancer	0.000268	0.00268	CcSEcCtD
Rabeprazole—Abdominal pain—Vinblastine—head and neck cancer	0.000268	0.00268	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen metabolism—GSTM1—head and neck cancer	0.000268	0.00753	CbGpPWpGaD
Rabeprazole—CYP1A1—Oxidative Stress—GPX1—head and neck cancer	0.000267	0.00751	CbGpPWpGaD
Rabeprazole—CYP2D6—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000265	0.00744	CbGpPWpGaD
Rabeprazole—Constipation—Hydroxyurea—head and neck cancer	0.000265	0.00264	CcSEcCtD
Rabeprazole—Pain—Hydroxyurea—head and neck cancer	0.000265	0.00264	CcSEcCtD
Rabeprazole—Neutropenia—Docetaxel—head and neck cancer	0.000264	0.00264	CcSEcCtD
Rabeprazole—CYP2C9—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000262	0.00738	CbGpPWpGaD
Rabeprazole—Weight increased—Docetaxel—head and neck cancer	0.000257	0.00257	CcSEcCtD
Rabeprazole—Vision blurred—Fluorouracil—head and neck cancer	0.000257	0.00257	CcSEcCtD
Rabeprazole—Weight decreased—Docetaxel—head and neck cancer	0.000256	0.00255	CcSEcCtD
Rabeprazole—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000255	0.00255	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen metabolism—CYP1A1—head and neck cancer	0.000254	0.00713	CbGpPWpGaD
Rabeprazole—Pneumonia—Docetaxel—head and neck cancer	0.000253	0.00253	CcSEcCtD
Rabeprazole—Anaemia—Fluorouracil—head and neck cancer	0.000252	0.00252	CcSEcCtD
Rabeprazole—Hypersensitivity—Vinblastine—head and neck cancer	0.00025	0.0025	CcSEcCtD
Rabeprazole—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00025	0.00249	CcSEcCtD
Rabeprazole—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000248	0.00248	CcSEcCtD
Rabeprazole—Myocardial infarction—Docetaxel—head and neck cancer	0.000247	0.00247	CcSEcCtD
Rabeprazole—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000247	0.00247	CcSEcCtD
Rabeprazole—Jaundice—Docetaxel—head and neck cancer	0.000246	0.00245	CcSEcCtD
Rabeprazole—Stomatitis—Docetaxel—head and neck cancer	0.000246	0.00245	CcSEcCtD
Rabeprazole—Conjunctivitis—Docetaxel—head and neck cancer	0.000245	0.00245	CcSEcCtD
Rabeprazole—Body temperature increased—Hydroxyurea—head and neck cancer	0.000245	0.00244	CcSEcCtD
Rabeprazole—Leukopenia—Fluorouracil—head and neck cancer	0.000244	0.00244	CcSEcCtD
Rabeprazole—Asthenia—Vinblastine—head and neck cancer	0.000243	0.00243	CcSEcCtD
Rabeprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.000239	0.00673	CbGpPWpGaD
Rabeprazole—Epistaxis—Docetaxel—head and neck cancer	0.000238	0.00237	CcSEcCtD
Rabeprazole—Convulsion—Fluorouracil—head and neck cancer	0.000236	0.00236	CcSEcCtD
Rabeprazole—Agranulocytosis—Docetaxel—head and neck cancer	0.000235	0.00235	CcSEcCtD
Rabeprazole—CYP1A2—Xenobiotics—CYP1A1—head and neck cancer	0.000233	0.00656	CbGpPWpGaD
Rabeprazole—Chest pain—Fluorouracil—head and neck cancer	0.000232	0.00232	CcSEcCtD
Rabeprazole—Myalgia—Fluorouracil—head and neck cancer	0.000232	0.00232	CcSEcCtD
Rabeprazole—Diarrhoea—Vinblastine—head and neck cancer	0.000232	0.00232	CcSEcCtD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—head and neck cancer	0.00023	0.00647	CbGpPWpGaD
Rabeprazole—Discomfort—Fluorouracil—head and neck cancer	0.000229	0.00229	CcSEcCtD
Rabeprazole—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000228	0.00228	CcSEcCtD
Rabeprazole—Rhinitis—Docetaxel—head and neck cancer	0.000227	0.00226	CcSEcCtD
Rabeprazole—Hepatitis—Docetaxel—head and neck cancer	0.000226	0.00226	CcSEcCtD
Rabeprazole—Confusional state—Fluorouracil—head and neck cancer	0.000224	0.00224	CcSEcCtD
Rabeprazole—Pharyngitis—Docetaxel—head and neck cancer	0.000224	0.00224	CcSEcCtD
Rabeprazole—Dizziness—Vinblastine—head and neck cancer	0.000224	0.00224	CcSEcCtD
Rabeprazole—CYP1A2—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000224	0.00631	CbGpPWpGaD
Rabeprazole—Urinary tract disorder—Docetaxel—head and neck cancer	0.000223	0.00223	CcSEcCtD
Rabeprazole—Oedema peripheral—Docetaxel—head and neck cancer	0.000223	0.00223	CcSEcCtD
Rabeprazole—Oedema—Fluorouracil—head and neck cancer	0.000223	0.00222	CcSEcCtD
Rabeprazole—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000223	0.00222	CcSEcCtD
Rabeprazole—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000222	0.00625	CbGpPWpGaD
Rabeprazole—Asthenia—Hydroxyurea—head and neck cancer	0.000222	0.00222	CcSEcCtD
Rabeprazole—Urethral disorder—Docetaxel—head and neck cancer	0.000222	0.00221	CcSEcCtD
Rabeprazole—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000218	0.00218	CcSEcCtD
Rabeprazole—Visual impairment—Docetaxel—head and neck cancer	0.000218	0.00218	CcSEcCtD
Rabeprazole—Tachycardia—Fluorouracil—head and neck cancer	0.000217	0.00217	CcSEcCtD
Rabeprazole—Vomiting—Vinblastine—head and neck cancer	0.000216	0.00215	CcSEcCtD
Rabeprazole—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—head and neck cancer	0.000215	0.00605	CbGpPWpGaD
Rabeprazole—Erythema multiforme—Docetaxel—head and neck cancer	0.000214	0.00214	CcSEcCtD
Rabeprazole—Headache—Vinblastine—head and neck cancer	0.000212	0.00212	CcSEcCtD
Rabeprazole—Anorexia—Fluorouracil—head and neck cancer	0.000212	0.00212	CcSEcCtD
Rabeprazole—Diarrhoea—Hydroxyurea—head and neck cancer	0.000212	0.00211	CcSEcCtD
Rabeprazole—Eye disorder—Docetaxel—head and neck cancer	0.000211	0.00211	CcSEcCtD
Rabeprazole—Hypotension—Fluorouracil—head and neck cancer	0.000208	0.00208	CcSEcCtD
Rabeprazole—CYP3A4—Estrogen metabolism—GSTM1—head and neck cancer	0.000206	0.00581	CbGpPWpGaD
Rabeprazole—Angiopathy—Docetaxel—head and neck cancer	0.000205	0.00205	CcSEcCtD
Rabeprazole—Dizziness—Hydroxyurea—head and neck cancer	0.000205	0.00204	CcSEcCtD
Rabeprazole—CYP2D6—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000204	0.00575	CbGpPWpGaD
Rabeprazole—Chills—Docetaxel—head and neck cancer	0.000203	0.00203	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000203	0.00203	CcSEcCtD
Rabeprazole—Arrhythmia—Docetaxel—head and neck cancer	0.000202	0.00202	CcSEcCtD
Rabeprazole—Nausea—Vinblastine—head and neck cancer	0.000201	0.00201	CcSEcCtD
Rabeprazole—Insomnia—Fluorouracil—head and neck cancer	0.000201	0.00201	CcSEcCtD
Rabeprazole—Paraesthesia—Fluorouracil—head and neck cancer	0.0002	0.002	CcSEcCtD
Rabeprazole—Alopecia—Docetaxel—head and neck cancer	0.0002	0.002	CcSEcCtD
Rabeprazole—Dyspnoea—Fluorouracil—head and neck cancer	0.000198	0.00198	CcSEcCtD
Rabeprazole—Somnolence—Fluorouracil—head and neck cancer	0.000198	0.00198	CcSEcCtD
Rabeprazole—Erythema—Docetaxel—head and neck cancer	0.000197	0.00197	CcSEcCtD
Rabeprazole—Malnutrition—Docetaxel—head and neck cancer	0.000197	0.00197	CcSEcCtD
Rabeprazole—Vomiting—Hydroxyurea—head and neck cancer	0.000197	0.00196	CcSEcCtD
Rabeprazole—Dyspepsia—Fluorouracil—head and neck cancer	0.000196	0.00196	CcSEcCtD
Rabeprazole—CYP3A4—Estrogen metabolism—CYP1A1—head and neck cancer	0.000196	0.00551	CbGpPWpGaD
Rabeprazole—Rash—Hydroxyurea—head and neck cancer	0.000195	0.00195	CcSEcCtD
Rabeprazole—Dermatitis—Hydroxyurea—head and neck cancer	0.000195	0.00195	CcSEcCtD
Rabeprazole—Headache—Hydroxyurea—head and neck cancer	0.000194	0.00194	CcSEcCtD
Rabeprazole—Decreased appetite—Fluorouracil—head and neck cancer	0.000194	0.00193	CcSEcCtD
Rabeprazole—Dysgeusia—Docetaxel—head and neck cancer	0.000193	0.00193	CcSEcCtD
Rabeprazole—Back pain—Docetaxel—head and neck cancer	0.00019	0.0019	CcSEcCtD
Rabeprazole—Pain—Fluorouracil—head and neck cancer	0.00019	0.0019	CcSEcCtD
Rabeprazole—Muscle spasms—Docetaxel—head and neck cancer	0.000189	0.00189	CcSEcCtD
Rabeprazole—Nausea—Hydroxyurea—head and neck cancer	0.000184	0.00184	CcSEcCtD
Rabeprazole—Feeling abnormal—Fluorouracil—head and neck cancer	0.000183	0.00183	CcSEcCtD
Rabeprazole—Anaemia—Docetaxel—head and neck cancer	0.000182	0.00182	CcSEcCtD
Rabeprazole—ATP4A—head—head and neck cancer	0.00018	0.0481	CbGeAlD
Rabeprazole—CYP3A4—Xenobiotics—CYP1A1—head and neck cancer	0.00018	0.00506	CbGpPWpGaD
Rabeprazole—CYP1A1—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000177	0.00499	CbGpPWpGaD
Rabeprazole—Urticaria—Fluorouracil—head and neck cancer	0.000177	0.00177	CcSEcCtD
Rabeprazole—Syncope—Docetaxel—head and neck cancer	0.000177	0.00176	CcSEcCtD
Rabeprazole—Leukopenia—Docetaxel—head and neck cancer	0.000176	0.00176	CcSEcCtD
Rabeprazole—Body temperature increased—Fluorouracil—head and neck cancer	0.000176	0.00176	CcSEcCtD
Rabeprazole—Palpitations—Docetaxel—head and neck cancer	0.000174	0.00174	CcSEcCtD
Rabeprazole—CYP1A2—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000173	0.00487	CbGpPWpGaD
Rabeprazole—Loss of consciousness—Docetaxel—head and neck cancer	0.000173	0.00173	CcSEcCtD
Rabeprazole—CYP3A4—Tamoxifen metabolism—CYP1A1—head and neck cancer	0.000173	0.00487	CbGpPWpGaD
Rabeprazole—Cough—Docetaxel—head and neck cancer	0.000172	0.00172	CcSEcCtD
Rabeprazole—Convulsion—Docetaxel—head and neck cancer	0.000171	0.0017	CcSEcCtD
Rabeprazole—Hypertension—Docetaxel—head and neck cancer	0.00017	0.0017	CcSEcCtD
Rabeprazole—Chest pain—Docetaxel—head and neck cancer	0.000168	0.00167	CcSEcCtD
Rabeprazole—Myalgia—Docetaxel—head and neck cancer	0.000168	0.00167	CcSEcCtD
Rabeprazole—Arthralgia—Docetaxel—head and neck cancer	0.000168	0.00167	CcSEcCtD
Rabeprazole—CYP1A1—PPARA activates gene expression—YAP1—head and neck cancer	0.000166	0.00467	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—head and neck cancer	0.000166	0.00466	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Fluorouracil—head and neck cancer	0.000164	0.00164	CcSEcCtD
Rabeprazole—Dry mouth—Docetaxel—head and neck cancer	0.000164	0.00164	CcSEcCtD
Rabeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—head and neck cancer	0.000163	0.00457	CbGpPWpGaD
Rabeprazole—Confusional state—Docetaxel—head and neck cancer	0.000162	0.00162	CcSEcCtD
Rabeprazole—Anaphylactic shock—Docetaxel—head and neck cancer	0.000161	0.00161	CcSEcCtD
Rabeprazole—Oedema—Docetaxel—head and neck cancer	0.000161	0.00161	CcSEcCtD
Rabeprazole—Shock—Docetaxel—head and neck cancer	0.000158	0.00158	CcSEcCtD
Rabeprazole—Pruritus—Fluorouracil—head and neck cancer	0.000158	0.00157	CcSEcCtD
Rabeprazole—Thrombocytopenia—Docetaxel—head and neck cancer	0.000157	0.00157	CcSEcCtD
Rabeprazole—Tachycardia—Docetaxel—head and neck cancer	0.000157	0.00157	CcSEcCtD
Rabeprazole—Anorexia—Docetaxel—head and neck cancer	0.000153	0.00153	CcSEcCtD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—head and neck cancer	0.000153	0.00429	CbGpPWpGaD
Rabeprazole—Diarrhoea—Fluorouracil—head and neck cancer	0.000152	0.00152	CcSEcCtD
Rabeprazole—CYP1A2—Phase II conjugation—NAT2—head and neck cancer	0.000152	0.00428	CbGpPWpGaD
Rabeprazole—Hypotension—Docetaxel—head and neck cancer	0.00015	0.0015	CcSEcCtD
Rabeprazole—Dizziness—Fluorouracil—head and neck cancer	0.000147	0.00147	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000146	0.00146	CcSEcCtD
Rabeprazole—Insomnia—Docetaxel—head and neck cancer	0.000145	0.00145	CcSEcCtD
Rabeprazole—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000145	0.00408	CbGpPWpGaD
Rabeprazole—Paraesthesia—Docetaxel—head and neck cancer	0.000144	0.00144	CcSEcCtD
Rabeprazole—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000144	0.00404	CbGpPWpGaD
Rabeprazole—Dyspnoea—Docetaxel—head and neck cancer	0.000143	0.00143	CcSEcCtD
Rabeprazole—Somnolence—Docetaxel—head and neck cancer	0.000143	0.00143	CcSEcCtD
Rabeprazole—Vomiting—Fluorouracil—head and neck cancer	0.000142	0.00141	CcSEcCtD
Rabeprazole—Dyspepsia—Docetaxel—head and neck cancer	0.000141	0.00141	CcSEcCtD
Rabeprazole—CYP1A1—mouth—head and neck cancer	0.000141	0.0375	CbGeAlD
Rabeprazole—Rash—Fluorouracil—head and neck cancer	0.00014	0.0014	CcSEcCtD
Rabeprazole—Dermatitis—Fluorouracil—head and neck cancer	0.00014	0.0014	CcSEcCtD
Rabeprazole—Decreased appetite—Docetaxel—head and neck cancer	0.00014	0.0014	CcSEcCtD
Rabeprazole—CYP1A1—Biological oxidations—NAT2—head and neck cancer	0.00014	0.00393	CbGpPWpGaD
Rabeprazole—Headache—Fluorouracil—head and neck cancer	0.000139	0.00139	CcSEcCtD
Rabeprazole—CYP1A1—Metapathway biotransformation—NAT2—head and neck cancer	0.000138	0.00387	CbGpPWpGaD
Rabeprazole—Constipation—Docetaxel—head and neck cancer	0.000137	0.00137	CcSEcCtD
Rabeprazole—Pain—Docetaxel—head and neck cancer	0.000137	0.00137	CcSEcCtD
Rabeprazole—Feeling abnormal—Docetaxel—head and neck cancer	0.000132	0.00132	CcSEcCtD
Rabeprazole—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000132	0.00372	CbGpPWpGaD
Rabeprazole—Nausea—Fluorouracil—head and neck cancer	0.000132	0.00132	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000131	0.00131	CcSEcCtD
Rabeprazole—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000131	0.00369	CbGpPWpGaD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TP53—head and neck cancer	0.000128	0.0036	CbGpPWpGaD
Rabeprazole—Body temperature increased—Docetaxel—head and neck cancer	0.000127	0.00127	CcSEcCtD
Rabeprazole—Abdominal pain—Docetaxel—head and neck cancer	0.000127	0.00127	CcSEcCtD
Rabeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000124	0.00349	CbGpPWpGaD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000123	0.00345	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—head and neck cancer	0.00012	0.00337	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—head and neck cancer	0.00012	0.00337	CbGpPWpGaD
Rabeprazole—CYP1A2—Tryptophan metabolism—CYP1A1—head and neck cancer	0.00012	0.00337	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Docetaxel—head and neck cancer	0.000118	0.00118	CcSEcCtD
Rabeprazole—Asthenia—Docetaxel—head and neck cancer	0.000115	0.00115	CcSEcCtD
Rabeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000114	0.00321	CbGpPWpGaD
Rabeprazole—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000114	0.00321	CbGpPWpGaD
Rabeprazole—Pruritus—Docetaxel—head and neck cancer	0.000114	0.00114	CcSEcCtD
Rabeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000113	0.00319	CbGpPWpGaD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000113	0.00318	CbGpPWpGaD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000113	0.00317	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000113	0.00317	CbGpPWpGaD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—head and neck cancer	0.000112	0.00315	CbGpPWpGaD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000112	0.00315	CbGpPWpGaD
Rabeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000112	0.00314	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	0.000112	0.00314	CbGpPWpGaD
Rabeprazole—Diarrhoea—Docetaxel—head and neck cancer	0.00011	0.0011	CcSEcCtD
Rabeprazole—Dizziness—Docetaxel—head and neck cancer	0.000106	0.00106	CcSEcCtD
Rabeprazole—CYP2D6—Biological oxidations—NAT2—head and neck cancer	0.000105	0.00296	CbGpPWpGaD
Rabeprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000104	0.00294	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000104	0.00293	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—NAT2—head and neck cancer	0.000104	0.00292	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	0.000104	0.00291	CbGpPWpGaD
Rabeprazole—ABCG2—parotid gland—head and neck cancer	0.000103	0.0275	CbGeAlD
Rabeprazole—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000103	0.00289	CbGpPWpGaD
Rabeprazole—Vomiting—Docetaxel—head and neck cancer	0.000102	0.00102	CcSEcCtD
Rabeprazole—Rash—Docetaxel—head and neck cancer	0.000101	0.00101	CcSEcCtD
Rabeprazole—Dermatitis—Docetaxel—head and neck cancer	0.000101	0.00101	CcSEcCtD
Rabeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000101	0.00283	CbGpPWpGaD
Rabeprazole—Headache—Docetaxel—head and neck cancer	0.000101	0.00101	CcSEcCtD
Rabeprazole—ABCG2—saliva-secreting gland—head and neck cancer	9.88e-05	0.0264	CbGeAlD
Rabeprazole—CYP1A1—parotid gland—head and neck cancer	9.8e-05	0.0261	CbGeAlD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—head and neck cancer	9.74e-05	0.00274	CbGpPWpGaD
Rabeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	9.68e-05	0.00272	CbGpPWpGaD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	9.55e-05	0.00269	CbGpPWpGaD
Rabeprazole—Nausea—Docetaxel—head and neck cancer	9.55e-05	0.000953	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—ATP7B—head and neck cancer	9.53e-05	0.00268	CbGpPWpGaD
Rabeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	9.26e-05	0.00261	CbGpPWpGaD
Rabeprazole—CYP3A4—Tryptophan metabolism—CYP1A1—head and neck cancer	9.24e-05	0.0026	CbGpPWpGaD
Rabeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	9.18e-05	0.00258	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—NAT2—head and neck cancer	8.9e-05	0.0025	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	8.8e-05	0.00247	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—NAT2—head and neck cancer	8.78e-05	0.00247	CbGpPWpGaD
Rabeprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	8.55e-05	0.0024	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—UROD—head and neck cancer	8.5e-05	0.00239	CbGpPWpGaD
Rabeprazole—CYP1A1—epithelium—head and neck cancer	8.18e-05	0.0218	CbGeAlD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	7.92e-05	0.00223	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	7.92e-05	0.00223	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	7.92e-05	0.00223	CbGpPWpGaD
Rabeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	7.85e-05	0.00221	CbGpPWpGaD
Rabeprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	7.79e-05	0.00219	CbGpPWpGaD
Rabeprazole—CYP1A2—Phase II conjugation—GSTM1—head and neck cancer	7.52e-05	0.00211	CbGpPWpGaD
Rabeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	7.47e-05	0.0021	CbGpPWpGaD
Rabeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	7.37e-05	0.00207	CbGpPWpGaD
Rabeprazole—CYP1A1—trachea—head and neck cancer	7.24e-05	0.0193	CbGeAlD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—head and neck cancer	7.12e-05	0.002	CbGpPWpGaD
Rabeprazole—CYP1A1—Biological oxidations—GSTM1—head and neck cancer	6.9e-05	0.00194	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—NAT2—head and neck cancer	6.87e-05	0.00193	CbGpPWpGaD
Rabeprazole—CYP1A1—Metapathway biotransformation—GSTM1—head and neck cancer	6.8e-05	0.00191	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	6.78e-05	0.00191	CbGpPWpGaD
Rabeprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—head and neck cancer	6.66e-05	0.00187	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—head and neck cancer	6.6e-05	0.00186	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	6.36e-05	0.00179	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	6.21e-05	0.00175	CbGpPWpGaD
Rabeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	6.06e-05	0.0017	CbGpPWpGaD
Rabeprazole—ABCG2—thyroid gland—head and neck cancer	6.03e-05	0.0161	CbGeAlD
Rabeprazole—CYP1A2—thyroid gland—head and neck cancer	5.8e-05	0.0155	CbGeAlD
Rabeprazole—CYP1A1—Metabolism—UROD—head and neck cancer	5.75e-05	0.00162	CbGpPWpGaD
Rabeprazole—CYP1A1—thyroid gland—head and neck cancer	5.73e-05	0.0153	CbGeAlD
Rabeprazole—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	5.64e-05	0.00159	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—head and neck cancer	5.61e-05	0.00158	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	5.57e-05	0.00157	CbGpPWpGaD
Rabeprazole—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	5.35e-05	0.0015	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	5.28e-05	0.00148	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	5.19e-05	0.00146	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	5.15e-05	0.00145	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	5.12e-05	0.00144	CbGpPWpGaD
Rabeprazole—CYP1A1—head—head and neck cancer	5.08e-05	0.0135	CbGeAlD
Rabeprazole—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	5.08e-05	0.00143	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	5.05e-05	0.00142	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	5.05e-05	0.00142	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—head and neck cancer	5.05e-05	0.00142	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	4.92e-05	0.00138	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	4.88e-05	0.00137	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	4.85e-05	0.00137	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	4.81e-05	0.00135	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—UROD—head and neck cancer	4.71e-05	0.00132	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.46e-05	0.00126	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—GSTM1—head and neck cancer	4.4e-05	0.00124	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—GSTM1—head and neck cancer	4.34e-05	0.00122	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—UROD—head and neck cancer	4.33e-05	0.00122	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—UROD—head and neck cancer	4.29e-05	0.00121	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—CYP1A1—head and neck cancer	4.17e-05	0.00117	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP1A1—head and neck cancer	4.11e-05	0.00116	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	4.05e-05	0.00114	CbGpPWpGaD
Rabeprazole—ABCG2—lymph node—head and neck cancer	3.75e-05	0.00999	CbGeAlD
Rabeprazole—CYP2D6—head—head and neck cancer	3.67e-05	0.00978	CbGeAlD
Rabeprazole—CYP1A2—Metabolism—UROD—head and neck cancer	3.67e-05	0.00103	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.65e-05	0.00103	CbGpPWpGaD
Rabeprazole—CYP1A1—lymph node—head and neck cancer	3.56e-05	0.00949	CbGeAlD
Rabeprazole—ABCG2—Metabolism—NAT2—head and neck cancer	3.53e-05	0.000992	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	3.39e-05	0.000955	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	3.35e-05	0.000941	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	3.33e-05	0.000936	CbGpPWpGaD
Rabeprazole—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	3.22e-05	0.000905	CbGpPWpGaD
Rabeprazole—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	3.17e-05	0.000893	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—DPYD—head and neck cancer	3.09e-05	0.00087	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—YAP1—head and neck cancer	2.94e-05	0.000826	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	2.84e-05	0.0008	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—UROD—head and neck cancer	2.83e-05	0.000796	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.54e-05	0.000713	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—NAT2—head and neck cancer	2.39e-05	0.000672	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—DPYD—head and neck cancer	2.09e-05	0.000589	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.08e-05	0.000584	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.05e-05	0.000578	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—YAP1—head and neck cancer	1.99e-05	0.000559	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NAT2—head and neck cancer	1.95e-05	0.00055	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.89e-05	0.000532	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.87e-05	0.000527	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NAT2—head and neck cancer	1.8e-05	0.000506	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NAT2—head and neck cancer	1.78e-05	0.000501	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—TYMS—head and neck cancer	1.76e-05	0.000496	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GSTM1—head and neck cancer	1.74e-05	0.00049	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—DPYD—head and neck cancer	1.71e-05	0.000482	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—GPX1—head and neck cancer	1.67e-05	0.000469	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP1A1—head and neck cancer	1.65e-05	0.000465	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—YAP1—head and neck cancer	1.63e-05	0.000457	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	1.62e-05	0.000455	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	1.6e-05	0.00045	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—DPYD—head and neck cancer	1.58e-05	0.000443	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—DPYD—head and neck cancer	1.56e-05	0.000439	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NAT2—head and neck cancer	1.52e-05	0.000428	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—YAP1—head and neck cancer	1.5e-05	0.000421	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.49e-05	0.00042	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—YAP1—head and neck cancer	1.48e-05	0.000417	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—DPYD—head and neck cancer	1.34e-05	0.000376	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.3e-05	0.000366	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—YAP1—head and neck cancer	1.27e-05	0.000356	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.22e-05	0.000344	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—TYMS—head and neck cancer	1.19e-05	0.000336	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GSTM1—head and neck cancer	1.18e-05	0.000332	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NAT2—head and neck cancer	1.18e-05	0.000331	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—GPX1—head and neck cancer	1.13e-05	0.000318	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.11e-05	0.000313	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.07e-05	0.0003	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—DPYD—head and neck cancer	1.03e-05	0.00029	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTGS2—head and neck cancer	9.82e-06	0.000276	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—YAP1—head and neck cancer	9.78e-06	0.000275	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—TYMS—head and neck cancer	9.76e-06	0.000275	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	9.72e-06	0.000273	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GSTM1—head and neck cancer	9.65e-06	0.000271	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	9.52e-06	0.000268	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—GPX1—head and neck cancer	9.24e-06	0.00026	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.19e-06	0.000258	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP1A1—head and neck cancer	9.15e-06	0.000257	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—TYMS—head and neck cancer	8.98e-06	0.000253	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—TYMS—head and neck cancer	8.9e-06	0.00025	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GSTM1—head and neck cancer	8.88e-06	0.00025	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GSTM1—head and neck cancer	8.8e-06	0.000248	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PTEN—head and neck cancer	8.57e-06	0.000241	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—GPX1—head and neck cancer	8.5e-06	0.000239	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—GPX1—head and neck cancer	8.43e-06	0.000237	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP1A1—head and neck cancer	8.42e-06	0.000237	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYP1A1—head and neck cancer	8.34e-06	0.000235	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	8.3e-06	0.000234	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—TYMS—head and neck cancer	7.61e-06	0.000214	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GSTM1—head and neck cancer	7.52e-06	0.000212	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.52e-06	0.000211	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—GPX1—head and neck cancer	7.2e-06	0.000203	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP1A1—head and neck cancer	7.13e-06	0.000201	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	6.85e-06	0.000193	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTGS2—head and neck cancer	6.65e-06	0.000187	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PIK3CA—head and neck cancer	6.04e-06	0.00017	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—TYMS—head and neck cancer	5.87e-06	0.000165	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	5.86e-06	0.000165	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GSTM1—head and neck cancer	5.8e-06	0.000163	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PTEN—head and neck cancer	5.8e-06	0.000163	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—GPX1—head and neck cancer	5.56e-06	0.000156	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYP1A1—head and neck cancer	5.5e-06	0.000155	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTGS2—head and neck cancer	5.44e-06	0.000153	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTGS2—head and neck cancer	5e-06	0.000141	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTGS2—head and neck cancer	4.96e-06	0.00014	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—AKT1—head and neck cancer	4.94e-06	0.000139	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PTEN—head and neck cancer	4.75e-06	0.000133	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PTEN—head and neck cancer	4.36e-06	0.000123	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PTEN—head and neck cancer	4.33e-06	0.000122	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTGS2—head and neck cancer	4.24e-06	0.000119	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PIK3CA—head and neck cancer	4.09e-06	0.000115	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PTEN—head and neck cancer	3.7e-06	0.000104	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PIK3CA—head and neck cancer	3.35e-06	9.42e-05	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—AKT1—head and neck cancer	3.34e-06	9.4e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTGS2—head and neck cancer	3.27e-06	9.2e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PIK3CA—head and neck cancer	3.08e-06	8.66e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PIK3CA—head and neck cancer	3.05e-06	8.59e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PTEN—head and neck cancer	2.85e-06	8.03e-05	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—AKT1—head and neck cancer	2.73e-06	7.69e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PIK3CA—head and neck cancer	2.61e-06	7.34e-05	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—AKT1—head and neck cancer	2.52e-06	7.07e-05	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—AKT1—head and neck cancer	2.49e-06	7.01e-05	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—AKT1—head and neck cancer	2.13e-06	5.99e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PIK3CA—head and neck cancer	2.01e-06	5.66e-05	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—AKT1—head and neck cancer	1.64e-06	4.63e-05	CbGpPWpGaD
